Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Huang Z, Ning B, Yang HS, Youngquist BM, Niu A, Lyon CJ, et al. Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. J Clin Invest. 2021;131(7).

Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, et al. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. J Rheumatol. 2021;48(4):541-547.

Ke Q, Dinalankara W, Younes L, Geman D, Marchionni L. Efficient representations of tumor diversity with paired DNA-RNA aberrations. PLoS Comput Biol. 2021;17(6):e1008944.

Fontan L, Goldstein R, Casalena G, Durant M, Teater MR, Wilson J, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021;137(6):788-800.

Mostyka M, Fulmer CG, Hissong EM, Yantiss RK. Crohn Disease Infrequently Affects the Appendix and Rarely Causes Granulomatous Appendicitis. Am J Surg Pathol. 2021.

Hansen G, Marino J, Wang Z-, Beavis KG, Rodrigo J, Labog K, et al. Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. J Clin Microbiol. 2021;59(2).

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.

Wangsiricharoen S, Wakely PE, Siddiqui MT, Ali SZ. Cytopathology of chondromyxoid fibroma: a case series and review of the literature. J Am Soc Cytopathol. 2021;10(4):366-381.

Yantiss RK, Qin L, He B, Crawford CV, Seshan S, Patel S, et al. Intestinal Abnormalities in Patients With SARS-CoV-2 Infection: Histopathologic Changes Reflect Mechanisms of Disease. Am J Surg Pathol. 2021.

Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham C-, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. Antimicrob Agents Chemother. 2021;65(11):e0120421.